SCHEMBL4186718

SCHEMBL4186718

COc1ccc(-c2nn(-c3ccccc3)cc2-c2ccc(C)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.65
MEN1 O00255 5/20 0.65
KMT2A Q03164 5/20 0.65
NPC1 O15118 3/20 0.65
KDM4E B2RXH2 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
MAPT P10636 2/20 0.65
ALDH1A1 P00352 2/20 0.65
HTT P42858 1/20 0.64
CDK2 P24941 3/20 0.64
CCNE1 P24864 1/20 0.64
AURKA O14965 1/20 0.61
TP53 P04637 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
NLRP3 Q96P20 1/20 0.61
ATM Q13315 1/20 0.61
CA12 O43570 2/20 0.61
CA9 Q16790 2/20 0.61
PTGS2 P35354 3/20 0.60
BRAF P15056 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13890469 0.93 CNR1 (0.61) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL13890467 0.90 MEN1 (0.68) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL4184361 0.87 PTGS2 (0.60) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL10028840 0.86 PTGS2 (0.67) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL7859639 0.83 MEN1 (0.72) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL4190133 0.81 MAPT (0.58) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL4193436 0.81 PTGS2 (0.58) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL28668102 0.81 BRAF (0.62) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL11837756 0.79 RAB9A (0.72) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL8206418 0.79 MAPKAPK2 (0.70) RAB9AMEN1KMT2ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071782-B2 Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2011-12-06 US disclosed
US-8071782-B2 Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2011-12-06 US disclosed
US-8071782-B2 Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2011-12-06 US disclosed
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2009-04-09 US disclosed
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2009-04-09 US disclosed
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles CYP3A4, CYP4B1, CYP2E1 RAB9A 3741/4885MEN1 1689/4885KMT2A 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.